SCHEMBL5315258

SCHEMBL5315258

CC(C)COC(=O)N1CCC(CNC(=O)OCc2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 10/20 0.56
CYP2D6 P10635 4/20 0.55
CYP2C9 P11712 4/20 0.55
TPSAB1 Q15661 3/20 0.53
TPSD1 Q9BZJ3 3/20 0.53
TPSG1 Q9NRR2 3/20 0.53
CYP3A4 P08684 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
HTT P42858 1/20 0.51
CYP2C19 P33261 1/20 0.50
F2 P00734 2/20 0.49
PRSS1 P07477 2/20 0.49
F13A1 P00488 1/20 0.49
TGM2 P21980 1/20 0.49
TGM1 P22735 1/20 0.49
PLG P00747 1/20 0.49
PRSS2 P07478 1/20 0.49
PRSS3 P35030 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29532829 0.90 GRIN2B (0.67) GRIN2BCYP2D6CYP2C9TPSAB1TPSD1
SCHEMBL5566410 0.89 CTSK (0.46) GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL1240612 0.84 TPSAB1 (0.58) GRIN2BCYP2D6CYP2C9TPSAB1TPSD1
SCHEMBL1241067 0.83 KDM4E (0.69) GRIN2BCYP2D6CYP2C9TPSAB1TPSD1
SCHEMBL3824687 0.83 CTSK (0.51) SMN1; SMN2NPC1RAB9AHTT
SCHEMBL25248629 0.82 GRIN2B (0.64) GRIN2BCYP2D6CYP2C9TPSAB1TPSD1
SCHEMBL5351275 0.81 KDM4E (0.62) GRIN2BCYP2D6CYP2C9TPSAB1TPSD1
SCHEMBL20135734 0.81 MEN1 (0.61) GRIN2BCYP2C9SMN1; SMN2NPC1RAB9A
SCHEMBL4076025 0.81 DPP4 (0.59) SMN1; SMN2NPC1RAB9A
SCHEMBL20660273 0.80 KDM4E (0.64) GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007068739-A1 4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS GLAXO GROUP LIMITED (GB) 2007-06-21 WO disclosed